New hope for hard-to-treat cancers: triple therapy targets HER2-positive tumors
Disease control
Recruiting now
This study tests a combination of two targeted drugs (trastuzumab and serplulimab) plus chemotherapy in 20 adults with advanced bile duct or bladder cancers that have stopped responding to standard treatments. The goal is to see if this triple therapy can shrink tumors and improv…
Phase: PHASE2 • Sponsor: Xiujuan Qu • Aim: Disease control
Last updated May 11, 2026 20:48 UTC